Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Apr;81(4):431-5.
doi: 10.1111/j.1349-7006.1990.tb02586.x.

Optimal treatment regimens for 5'-deoxy-5-fluorouridine, with or without (E)-5-(2-bromovinyl)-2'-deoxyuridine, against various tumors in mice

M Iigo  1 , M Miwa, E De Clercq
Affiliations

Optimal treatment regimens for 5'-deoxy-5-fluorouridine, with or without (E)-5-(2-bromovinyl)-2'-deoxyuridine, against various tumors in mice

M Iigo et al. Jpn J Cancer Res. 1990 Apr.

Abstract

The antitumor activity of 5'-deoxy-5-fluorouridine (DFUR), a prodrug of 5-fluorouracil (5-FU), is markedly enhanced if DFUR treatment is combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU). Combined oral administration of DFUR (10 mg/kg) and BVDU (10 mg/kg) three times (every 3 h) per day for 5 days afforded greater antitumor activity than a single dose of DFUR (300 mg/kg/day) for 5 days in mice bearing either adenocarcinoma 755 or Lewis lung carcinoma, while in the colon 26 system the antitumor effects of both treatment regimens were equivalent. Thus, a low-dose regimen of DFUR when combined with BVDU provides a similar or greater antitumor activity than a high-dose regimen of DFUR that is not combined with BVDU. The area under the curve of plasma 5-FU following a treatment with the combination of DFUR (10 mg/kg) and BVDU (10 mg/kg) was equal to that following DFUR (300 mg/kg) treatment.

PubMed Disclaimer

References

    1. ) Iigo , M. , Araki , E. , Nakajima , Y. , Hoshi , A. and De Clercq , E.Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5‐fluorouracil against adenocar‐cinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5‐fluorouracil levels . Biochem. Pharmacol. , 37 , 1609 – 1613 ( 1988. ). - PubMed
    1. ) Armstrong , R. D. and Diasio , R. B.Selective activation of 5′‐deoxy‐5‐fluorouridine by tumor cells as basis for an improved therapeutic index . Cancer Res. , 41 , 4891 – 4894 ( 1981. ). - PubMed
    1. ) Au , J. L‐S. , Rustum , Y. M. , Minowada , J. and Srivastave , B. I. S.Differential selectivity of 5‐fluorouracil and 5′‐deoxy‐5‐fluorouridine in cultured human B lymphocytes and mouse L1210 leukemia . Biochem. Pharmacol. , 32 , 541 – 546 ( 1983. ). - PubMed
    1. ) Ishitsuka , H. , Miwa , M. , Takemoto , K. , Fukuoka , K. , Itoga , A. and Maruyama , H. B.Role of uridine phosphorylase for antitumor activity of 5′‐deoxy‐5‐fluorouridine . Gann , 71 , 112 – 123 ( 1980. ). - PubMed
    1. ) Iigo , M. , Nishikata , K. , Nakajima , Y. , Hoshi , A. , Okudaira , N. , Odagiri , H. and De Clercq , E.Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5′‐deoxy‐5‐fluorouridine against adenocarcinoma 755 in mice: correlation with pharmacokinetics of plasma 5‐fluorouracil levels . Biochem. Pharmacol. , 38 , 1885 – 1889 ( 1989. ). - PubMed

Publication types

MeSH terms

LinkOut - more resources